vs
Side-by-side financial comparison of IRIDEX CORP (IRIX) and John Marshall Bancorp, Inc. (JMSB). Click either name above to swap in a different company.
John Marshall Bancorp, Inc. is the larger business by last-quarter revenue ($16.8M vs $14.7M, roughly 1.1× IRIDEX CORP). Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs 11.9%).
IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
IRIX vs JMSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $14.7M | $16.8M |
| Net Profit | — | $6.1M |
| Gross Margin | 37.2% | — |
| Operating Margin | — | — |
| Net Margin | — | 36.3% |
| Revenue YoY | -69.7% | — |
| Net Profit YoY | — | 26.8% |
| EPS (diluted) | — | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $16.8M | ||
| Q4 25 | $14.7M | $16.4M | ||
| Q3 25 | $12.5M | $16.3M | ||
| Q2 25 | $13.6M | $15.4M | ||
| Q1 25 | $11.9M | $14.6M | ||
| Q4 24 | $12.7M | $14.3M | ||
| Q3 24 | $11.6M | $13.8M | ||
| Q2 24 | $12.6M | $12.6M |
| Q1 26 | — | $6.1M | ||
| Q4 25 | — | $5.9M | ||
| Q3 25 | $-1.6M | $5.4M | ||
| Q2 25 | $-994.0K | $5.1M | ||
| Q1 25 | $-1.7M | $4.8M | ||
| Q4 24 | $-834.0K | $4.8M | ||
| Q3 24 | $-1.9M | $4.2M | ||
| Q2 24 | $-2.7M | $3.9M |
| Q1 26 | — | — | ||
| Q4 25 | 37.2% | — | ||
| Q3 25 | 32.1% | — | ||
| Q2 25 | 34.5% | — | ||
| Q1 25 | 42.5% | — | ||
| Q4 24 | 44.0% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 40.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 47.4% | ||
| Q3 25 | -11.3% | 42.2% | ||
| Q2 25 | -6.9% | 42.7% | ||
| Q1 25 | -1.7% | 42.4% | ||
| Q4 24 | -3.9% | 42.5% | ||
| Q3 24 | -16.1% | 38.8% | ||
| Q2 24 | -20.9% | 39.7% |
| Q1 26 | — | 36.3% | ||
| Q4 25 | — | 36.2% | ||
| Q3 25 | -12.6% | 33.2% | ||
| Q2 25 | -7.3% | 33.1% | ||
| Q1 25 | -14.2% | 32.9% | ||
| Q4 24 | -6.6% | 33.3% | ||
| Q3 24 | -16.7% | 30.7% | ||
| Q2 24 | -21.2% | 30.9% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | — | $0.41 | ||
| Q3 25 | $-0.09 | $0.38 | ||
| Q2 25 | $-0.06 | $0.36 | ||
| Q1 25 | $-0.10 | $0.34 | ||
| Q4 24 | $-0.05 | $0.33 | ||
| Q3 24 | $-0.12 | $0.30 | ||
| Q2 24 | $-0.16 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | $150.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $268.1M |
| Total Assets | $29.2M | $2.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $150.2M | ||
| Q4 25 | $6.0M | $130.0M | ||
| Q3 25 | $5.6M | $163.6M | ||
| Q2 25 | $6.8M | $116.9M | ||
| Q1 25 | $7.2M | $169.1M | ||
| Q4 24 | $2.4M | $122.5M | ||
| Q3 24 | $3.9M | $177.2M | ||
| Q2 24 | $4.1M | $182.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $80.9M | ||
| Q3 25 | — | $80.9M | ||
| Q2 25 | — | $80.8M | ||
| Q1 25 | — | $80.8M | ||
| Q4 24 | $1.0M | $80.8M | ||
| Q3 24 | $1.4M | $80.8M | ||
| Q2 24 | — | $24.7M |
| Q1 26 | — | $268.1M | ||
| Q4 25 | — | $265.6M | ||
| Q3 25 | $4.7M | $259.7M | ||
| Q2 25 | $6.1M | $253.7M | ||
| Q1 25 | $852.0K | $253.0M | ||
| Q4 24 | $2.1M | $246.6M | ||
| Q3 24 | $2.6M | $243.1M | ||
| Q2 24 | $4.2M | $235.3M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $29.2M | $2.3B | ||
| Q3 25 | $28.4M | $2.3B | ||
| Q2 25 | $31.6M | $2.3B | ||
| Q1 25 | $34.2M | $2.3B | ||
| Q4 24 | $29.1M | $2.2B | ||
| Q3 24 | $30.2M | $2.3B | ||
| Q2 24 | $31.2M | $2.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | 0.48× | 0.33× | ||
| Q3 24 | 0.53× | 0.33× | ||
| Q2 24 | — | 0.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRIX
Segment breakdown not available.
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
